Next-generation PARP1-selective inhibition and combination therapy in breast cancer
PARP inhibitors have transformed treatment of BRCA1/2 -mutated breast cancer but remain limited by acquired resistance, restricted activity in homologous recombination–proficient tumors, and PARP2-related toxicity. This review examines two advances redefining the class: next-generation PARP1-selective inhibitors with improved therapeutic indices, and rational combinations with DNA-repair, epigenetic, immune, endocrine, and antibody-drug conjugate partners. Together, these strategies mark a shift from monotherapy toward mechanism-based combinations that broaden benefit across breast cancer subtypes.
Authors
- Tejaswini Parlapalle Reddy (ORCID: https://orcid.org/0000-0003-1806-1701)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Bora Lim (ORCID: https://orcid.org/0000-0002-4182-6058)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-09-30
- DOI
- https://doi.org/10.1038/s41523-026-01056-2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00